






Murphy, D. J. and Blyth, K. G. (2017) Predicting lung cancer recurrence 
from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA 
analysis depicts early-stage lung cancer evolution'. Cell Death and 
Differentiation, 24(9), pp. 1473-1474. (doi:10.1038/cdd.2017.97) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
































Predicting	  lung	  cancer	  recurrence	  from	  circulating	  tumour	  DNA	  
	  








1	  Institute	  of	  Cancer	  Sciences,	  University	  of	  Glasgow,	  Glasgow,	  G61	  1BD,	  United	  Kingdom	  
2	  Pleural	  Disease	  Unit,	  Queen	  Elizabeth	  University	  Hospital,	  Glasgow,	  UK 
3	  Institute	  of	  Infection,	  Immunity	  and	  Inflammation,	  University	  of	  Glasgow,	  UK	  
	  
*	  Corresponding	  author:	  
Daniel.murphy@glasgow.ac.uk	  
+44	  141	  330	  8710	  
	   	  
Cancers	  of	  the	  lung	  kill	  more	  people	  worldwide	  than	  cancers	  of	  any	  other	  organ.	  	  Approximately	  
16%	  of	  lung	  cancer	  cases	  are	  suitable	  for	  surgical	  resection,	  however	  fatal	  disease	  recurs	  in	  some	  
30-­‐70%	  of	  resected	  cases	  (1,	  2).	   	  Better	  predictive	  indicators	  of	  tumour	  recurrence	  could	  lead	  to	  
improved	   treatment	   outcomes	   in	   patients	   with	   relapse	   while	   sparing	   others	   from	   unnecessary	  
procedures.	   	   The	   study	   by	   Abbosh	   et	   al.	   used	   patient-­‐specific	  multiplex	   PCR	   coupled	  with	   next	  
generation	   sequencing	   (NGS)	   to	   examine	   plasma-­‐borne	   tumour-­‐derived	   cell-­‐free	   DNA	   (alt.	  
circulating	  tumour	  DNA,	  ctDNA)	  as	  a	  predictive	  biomarker	  of	  post-­‐resection	  tumour	  recurrence	  in	  
patients	  with	  early	   stage	  NSCLC	   (3).	   	  Conducted	  under	   the	  auspices	  of	   the	  TRACERx	  clinical	   trial	  
(TRAcking	  non	  small	  cell	  lung	  Cancer	  Evolution	  through	  therapy	  [Rx])	  (4),	  the	  study	  addressed	  the	  
clinico-­‐pathologic	   determinants	   of	   ctDNA,	   the	   clonal/sub-­‐clonal	   fidelity	   of	   ctDNA,	   and	   the	  
potential	  for	  ctDNA	  detection	  and	  characterization	  not	  only	  to	  predict	  relapse	  incidence	  but,	  more	  
importantly,	  to	  identify	  potentially	  druggable	  biological	  features	  of	  recurrent	  disease.	  
	   The	   presence	   of	   cell-­‐free	   DNA	   (cfDNA)	   in	   plasma	   has	   long	   been	   appreciated	   to	   rise	   in	  
response	  to	  a	  spectrum	  of	  physiological	  and	  disease	  states	  (5).	  	  The	  distinction	  of	  ctDNA	  depends	  
on	  detection	  of	  tumour-­‐associated	  mutations	   in	  circulating	  cfDNA,	  typically	   in	  the	  form	  of	  single	  
nucleotide	   variants	   (SNVs).	   	  Using	  a	   threshold	  of	  detection	  of	  2	   SNVs	   to	   score	  a	  plasma	   sample	  
positive	  for	  ctDNA,	  Abbosh	  &	  colleagues	  showed	  clear	  correlations	  of	  ctDNA	  presence	   in	  plasma	  
with	   primary	   tumour	   proliferative	   index	   (Ki67);	   lymphovascular	   invasion;	   and	   degree	   of	   tumour	  
necrosis.	   	   They	  also	   revealed	  a	   strong	   correlation	  with	   tumour	  volume	   that	  has	   implications	   for	  
detection	  of	  minimal	  or	  residual	  disease	  (see	  below).	  	  Strikingly,	  the	  study	  revealed	  a	  preferential	  
association	  between	  presence	  of	  ctDNA	  and	  tumour	  histological	  subtype:	  whereas	  pre-­‐operative	  
plasma	  from	  30/31	  lung	  squamous	  cell	  carcinoma	  (LuSC)	  patients	  scored	  positive,	  only	  11/58	  cases	  
of	  lung	  adenocarcinoma	  (LuAD)	  scored	  positive.	  	  Importantly,	  this	  pattern	  was	  preserved	  in	  a	  sub-­‐
group	  comparison	  of	  stage-­‐matched	  (stage	  I)	  LuSC	  and	  LuAD	  cases	  (16/17	  (94%)	  detected	  vs.	  5/39	  
(13%)	   detected,	   respectively).	   Furthermore,	   non-­‐adenocarcinoma	   histology	   was	   the	   single	  
strongest	  determinant	  of	  ctDNA	  presence	  (3).	  	  This	  may	  reflect	  a	  greater	  propensity	  for	  LuSC	  to	  be	  
micro-­‐metastatic,	  even	  at	  Stage	  I,	  but	  also	  suggests	  that	  ctDNA	  analysis	  will	  have	  little	  value	  for	  a	  
large	  proportion	  of	  LuAD	  cases.	  
	   The	   next	   phase	   of	   the	   study	   compared	   longitudinal	   detection	   of	   ctDNA,	   pre-­‐	   and	   post-­‐
operatively,	  with	  periodic	  clinical	  assessment	  and	  chest	  radiography,	  in	  a	  subset	  of	  NSCLC	  samples	  
including	  both	  LuSC	  and	  LuAD.	  	  	  CtDNA	  was	  detected	  in	  13	  of	  14	  relapse	  cases,	  on	  average	  some	  
70	  days	  prior	  to	  clinical	  confirmation	  by	  CT	  imaging.	  	  On	  the	  other	  hand,	  ctDNA	  was	  detected	  in	  1	  
of	  10	  cases	  with	  no	  evidence	  of	  clinical	  relapse	  (at	  the	  time	  of	  publication).	  	  In	  a	  small	  number	  of	  
cases,	   tracking	   the	   number	   of	   SNVs	   post-­‐operatively	   appeared	   to	   reflect	   resistance	   or	   indeed	  
sensitivity	   to	   adjuvant	   chemotherapy,	   as	   three	  patients	  whose	  plasma	   SNV	  numbers	   rose	  while	  
receiving	   chemotherapy	   all	   relapsed	   within	   1	   year,	   while	   one	   patient	   that	   exhibited	   a	   sharp	  
decrease	   in	   SNVs	   remained	   relapse-­‐free	   688	   days	   later	   (3).	   While	   these	   data	   are	   certainly	  
encouraging,	  they	  suggest	  that	  further	  studies	  in	  larger	  cohorts	  are	  warranted.	  
	   The	   methods	   used	   to	   define	   recurrent	   disease	   might	   also	   require	   adjustment	   in	   future	  
studies.	  This	  would	  allow	  clearer	  definition	  of	  the	  temporal	  relationship	  between	  the	  emergence	  
of	  recurrent	  disease	  and	  detection	  of	  ctDNA.	  In	  TRACERx,	  a	  standard	  UK	  follow-­‐up	  schedule	  was	  
used,	  involving	  clinical	  review	  (usually	  limited	  to	  discussion	  of	  symptoms	  and	  clinical	  examination)	  
combined	   with	   a	   chest	   radiograph,	   without	   any	   protocolised	   cross-­‐sectional	   imaging	   (2).	   CT	  
scanning	  was	  only	  triggered	  by	  new	  symptoms	  or	  a	  change	  in	  chest	  radiographic	  appearances.	  This	  
practice	   is	   based	   on	   a	   lack	   of	   high	   quality	   evidence	   that	   scheduled	   CT	   surveillance	   improves	  
survival	   (6,	   7)	   despite	   previous	   data	   showing	   improved	   sensitivity	   for	   early	   detection	   using	  
surveillance	  CT	  (8).	  As	  a	  result	  it	  is	  highly	  likely	  that	  tumour	  recurrence	  had	  in	  fact	  developed	  well	  
before	   the	   70	   days	   described	   between	   the	   emergence	   of	   ctDNA	   and	   ‘clinical’	   detection.	   	   For	  
similar	   reasons	   is	  difficult	   to	  draw	  conclusions	   from	   the	   report	  of	   ctDNA	  detection	   in	   the	   single	  
patient	  described	  ‘without	  clinical	  evidence	  of	  recurrence’	  given	  the	  low	  sensitivity	  of	  the	  follow-­‐
up	   methods	   use.	   The	   authors’	   description	   of	   good	   correlation	   between	   tumour	   volume	   at	  
diagnosis	  and	  ctDNA	  variant	  allele	  frequency	  (VAF),	  and	  an	  ability	  to	  detect	  ctDNA	  shed	  from	  tiny	  
primary	  tumours	  would	  tend	  to	  support	  this.	  	  Therefore,	  future	  studies	  incorporating	  US-­‐style	  lung	  
cancer	   follow-­‐up,	   which	   includes	   6-­‐monthly	   CT	   scans	   for	   2	   years	   post-­‐surgery	   (9),	   are	   likely	   to	  
better	  define	   the	   relationship	  between	   the	  emergence	  of	   recurrent	  disease	  and	  ctDNA,	  and	   the	  
true	  lead-­‐time	  benefit	  of	  this	  new	  and	  exciting	  technology.	  
Perhaps	   the	   greatest	   value	   in	   the	   approach	   derives	   from	   analysis	   of	   the	   actual	   SNVs	  
detected,	   many	   of	   which	   reflect	   functional	   mutations	   present	   in	   the	   primary	   tumours.	   	   Multi-­‐
region	  NGS	  of	  the	  primary	  tumours	  allowed	  the	  researchers	  to	  assemble	  phylogenetic	  “trees”	  of	  
each	   tumour,	   distinguishing	   clonal	   mutations	   present	   in	   all	   tumour	   regions	   from	   sub-­‐clonal	  
mutations	  occurring	   in	  a	   subset	  of	   tumour	   regions.	   	  Transposing	   this	  analysis	  onto	   the	  detected	  
ctDNA	   revealed	   which	   tumour	   subclones	   were	   represented	   in	   ctDNA	   pre	   and	   post-­‐operatively.	  	  
Analysis	  of	  clonal	  dynamics	  during	  tumour	  relapse	  shed	  light	  on	  whether	  recurring	  tumours	  were	  
likely	   to	  be	  mono-­‐	  or	  oligo-­‐clonal	  and,	   in	   the	   former	   instance,	  which	  tumour	  subpopulation	  was	  
driving	  tumour	  relapse.	  	  The	  power	  of	  this	  approach	  to	  potentially	  guide	  therapy	  is	  exemplified	  by	  
one	   particular	   case,	   in	   which	   ctDNA	   analysis	   during	   relapse	   indicated	   re-­‐emergence	   of	   clonal	  
disease	   that	  mapped	  back	   to	   a	   particular	   subclone	  of	   the	  primary	   tumour	   containing	   an	   ERBB2	  
amplification.	  	  However,	  for	  reasons	  that	  are	  unclear,	  the	  patient	  was	  subsequently	  administered	  
an	  EGFR-­‐selective	   inhibitor	   (Erlotinib)	  whereas,	   in	  our	  opinion,	  an	  ERBB2-­‐selective	  or	  multi-­‐ERBB	  
inhibitor	  (eg.	  Afatinib)	  would	  likely	  have	  yielded	  greater	  benefit	  (10-­‐12).	  
Overall,	   the	   study	   quite	   firmly	   establishes	   the	   feasibility	   of	   longitudinal	   monitoring	   of	  
ctDNA	  as	  a	  surrogate	  for	  tumour	  recurrence,	  at	  least	  in	  the	  LuSC	  subtype	  of	  NSCLC.	  	  The	  authors	  
quite	   rightly	   point	   out	   that	   the	   approach	   is	   presently	   limited	   by	   cost	   and	   by	   the	   sensitivity	   of	  
current	  ctDNA	  platforms,	  neither	  of	  which	  are	  insurmountable	  in	  the	  medium	  term.	  	  The	  greater	  
challenges	  moving	  forward	  will	  be	  to	  apply	  this	  technology	  meaningfully	  towards	  the	  vast	  majority	  
of	  NSCLC	  cases	  that	  are	  unsuitable	  for	  surgical	  resection	  and	  indeed	  to	  better	  define	  the	  subgroup	  
of	  LuAD	  cases	  that	  might	  benefit	  from	  the	  approach.	  
	  
References	  
1.	   Pignon	   JP,	   Tribodet	   H,	   Scagliotti	   GV,	   Douillard	   JY,	   Shepherd	   FA,	   Stephens	   RJ,	   et	   al.	   Lung	  
adjuvant	   cisplatin	   evaluation:	   a	   pooled	   analysis	   by	   the	   LACE	   Collaborative	   Group.	   J	   Clin	   Oncol.	  
2008;26(21):3552-­‐9.	  
2.	   	  The	  Diagnosis	  and	  Treatment	  of	  Lung	  Cancer	   (Update).	  National	   Institute	   for	  Health	  and	  
Clinical	  Excellence:	  Guidance.	  Cardiff	  (UK)2011.	  
3.	   Abbosh	   C,	   Birkbak,	   N.J.,	   Wilson,	   G.A.,	   Jamal-­‐Hanjani,	   M.,	   Constantin,	   T.,	   Salari,	   R.	   et	   al.	  
Phylogenetic	  ctDNA	  analysis	  depicts	  early	  stage	  lung	  cancer	  evolution.	  Nature.	  2017;In	  Press.	  
4.	   Jamal-­‐Hanjani	  M,	  Hackshaw	  A,	  Ngai	  Y,	  Shaw	  J,	  Dive	  C,	  Quezada	  S,	  et	  al.	  Tracking	  genomic	  
cancer	  evolution	  for	  precision	  medicine:	  the	  lung	  TRACERx	  study.	  PLoS	  Biol.	  2014;12(7):e1001906.	  
5.	   Wan	   JC,	   Massie	   C,	   Garcia-­‐Corbacho	   J,	   Mouliere	   F,	   Brenton	   JD,	   Caldas	   C,	   et	   al.	   Liquid	  
biopsies	   come	   of	   age:	   towards	   implementation	   of	   circulating	   tumour	   DNA.	   Nat	   Rev	   Cancer.	  
2017;17(4):223-­‐38.	  
6.	   Calman	   L,	   Beaver	   K,	  Hind	  D,	   Lorigan	   P,	   Roberts	   C,	   Lloyd-­‐Jones	  M.	   Survival	   benefits	   from	  
follow-­‐up	   of	   patients	  with	   lung	   cancer:	   a	   systematic	   review	   and	  meta-­‐analysis.	   J	   Thorac	   Oncol.	  
2011;6(12):1993-­‐2004.	  
7.	   Crabtree	  TD,	  Puri	  V,	  Chen	  SB,	  Gierada	  DS,	  Bell	  JM,	  Broderick	  S,	  et	  al.	  Does	  the	  method	  of	  
radiologic	  surveillance	  affect	  survival	  after	  resection	  of	  stage	  I	  non-­‐small	  cell	  lung	  cancer?	  J	  Thorac	  
Cardiovasc	  Surg.	  2015;149(1):45-­‐52,	  3	  e1-­‐3.	  
8.	   Hanna	  WC,	  Paul	  NS,	  Darling	  GE,	  Moshonov	  H,	  Allison	  F,	  Waddell	   TK,	   et	   al.	  Minimal-­‐dose	  
computed	  tomography	  is	  superior	  to	  chest	  x-­‐ray	  for	  the	  follow-­‐up	  and	  treatment	  of	  patients	  with	  
resected	  lung	  cancer.	  J	  Thorac	  Cardiovasc	  Surg.	  2014;147(1):30-­‐3.	  
9.	   Colt	  HG,	  Murgu	  SD,	  Korst	  RJ,	  Slatore	  CG,	  Unger	  M,	  Quadrelli	  S.	  Follow-­‐up	  and	  surveillance	  
of	  the	  patient	  with	  lung	  cancer	  after	  curative-­‐intent	  therapy:	  Diagnosis	  and	  management	  of	  lung	  
cancer,	  3rd	  ed:	  American	  College	  of	  Chest	  Physicians	  evidence-­‐based	  clinical	  practice	  guidelines.	  
Chest.	  2013;143(5	  Suppl):e437S-­‐54S.	  
10.	   Suzawa	   K,	   Toyooka	   S,	   Sakaguchi	  M,	  Morita	  M,	   Yamamoto	  H,	   Tomida	   S,	   et	   al.	   Antitumor	  
effect	   of	   afatinib,	   as	   a	   human	   epidermal	   growth	   factor	   receptor	   2-­‐targeted	   therapy,	   in	   lung	  
cancers	  harboring	  HER2	  oncogene	  alterations.	  Cancer	  Sci.	  2016;107(1):45-­‐52.	  
11.	   Schuler	   M,	   Yang	   JC,	   Park	   K,	   Kim	   JH,	   Bennouna	   J,	   Chen	   YM,	   et	   al.	   Afatinib	   beyond	  
progression	  in	  patients	  with	  non-­‐small-­‐cell	  lung	  cancer	  following	  chemotherapy,	  erlotinib/gefitinib	  
and	  afatinib:	  phase	  III	  randomized	  LUX-­‐Lung	  5	  trial.	  Ann	  Oncol.	  2016;27(3):417-­‐23.	  
12.	   Mazieres	   J,	   Barlesi	   F,	   Filleron	   T,	   Besse	   B,	   Monnet	   I,	   Beau-­‐Faller	   M,	   et	   al.	   Lung	   cancer	  
patients	  with	  HER2	  mutations	  treated	  with	  chemotherapy	  and	  HER2-­‐targeted	  drugs:	  results	  from	  




Distinct	   tumour	   sub-­‐populations	   are	   characterised	   by	   the	   spectrum	   of	   mutations	   present:	  	  
Mutations	   common	   to	   all	   regions	   are	   classed	   as	   clonal	   whereas	   those	   present	   in	   a	   subset	   of	  
regions	  are	  classed	  sub-­‐clonal.	  	  Shedding	  of	  detectable	  ctDNA	  from	  different	  tumour	  regions	  into	  
circulation	  is	  correlated	  to	  the	  volume	  of	  the	  tumour	  subclone.	  	  Clonal	  mutations	  are	  more	  likely	  
to	  be	  detected	  than	  subclonal	  mutations.	  
